カテゴリ： 世界, 医療/バイオ, QYResearch

急性骨髄性白血病（AML）バイオマーカー検査の世界市場2023年：遺伝性急性骨髄性白血病（AML）バイオマーカー、エピジェネティック急性骨髄性白血病（AML）バイオマーカー、プロテオーム性急性骨髄性白血病（AML）バイオマーカー

■ 英語タイトル：Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA7419）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA7419
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：86
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[急性骨髄性白血病（AML）バイオマーカー検査の世界市場2023年：遺伝性急性骨髄性白血病（AML）バイオマーカー、エピジェネティック急性骨髄性白血病（AML）バイオマーカー、プロテオーム性急性骨髄性白血病（AML）バイオマーカー]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査資料は急性骨髄性白血病（AML）バイオマーカー検査のグローバル市場について調査・分析し、世界の急性骨髄性白血病（AML）バイオマーカー検査市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（遺伝性急性骨髄性白血病（AML）バイオマーカー、エピジェネティック急性骨髄性白血病（AML）バイオマーカー、プロテオーム性急性骨髄性白血病（AML）バイオマーカー）、用途別セグメント分析（病院、がん診断センター、研究所、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Abbott Laboratories、Novartis AG、Thermo Fisher Scientific、Cancer Genetics Inc.、Sysmex Corporation、Epigenomics AG、BioMerieux SA、Skyline DX B.V.などが含まれています。急性骨髄性白血病（AML）バイオマーカー検査のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、急性骨髄性白血病（AML）バイオマーカー検査市場規模を算出する際に考慮しました。

・急性骨髄性白血病（AML）バイオマーカー検査市場の概要
- 急性骨髄性白血病（AML）バイオマーカー検査の種類別セグメント
- 世界の急性骨髄性白血病（AML）バイオマーカー検査市場規模：タイプ別分析（遺伝性急性骨髄性白血病（AML）バイオマーカー、エピジェネティック急性骨髄性白血病（AML）バイオマーカー、プロテオーム性急性骨髄性白血病（AML）バイオマーカー）
- 急性骨髄性白血病（AML）バイオマーカー検査の用途別セグメント
- 世界の急性骨髄性白血病（AML）バイオマーカー検査市場規模：用途別分析（病院、がん診断センター、研究所、その他）
- 世界の急性骨髄性白血病（AML）バイオマーカー検査市場規模予測（2018年-2029年）

・急性骨髄性白血病（AML）バイオマーカー検査市場の成長トレンド
- 急性骨髄性白血病（AML）バイオマーカー検査の地域別市場規模（2018年-2029年）
- 急性骨髄性白血病（AML）バイオマーカー検査市場ダイナミクス
- 急性骨髄性白血病（AML）バイオマーカー検査の業界動向
- 急性骨髄性白血病（AML）バイオマーカー検査市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・種類別セグメント：遺伝性急性骨髄性白血病（AML）バイオマーカー、エピジェネティック急性骨髄性白血病（AML）バイオマーカー、プロテオーム性急性骨髄性白血病（AML）バイオマーカー
- 世界の急性骨髄性白血病（AML）バイオマーカー検査のタイプ別市場規模（2018年-2023年）
- 世界の急性骨髄性白血病（AML）バイオマーカー検査のタイプ別市場規模（2024年-2029年）

・用途別セグメント：病院、がん診断センター、研究所、その他
- 世界の急性骨髄性白血病（AML）バイオマーカー検査の用途別市場規模（2018年-2023年）
- 世界の急性骨髄性白血病（AML）バイオマーカー検査の用途別市場規模（2024年-2029年）

・急性骨髄性白血病（AML）バイオマーカー検査の地域別市場規模
- 北米の急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年）
- 米国の急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年）
- ヨーロッパの急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年）
- アジア太平洋の急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年）
- 中国の急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年）
- 日本の急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年）
- 韓国の急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年）
- インドの急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年）
- オーストラリアの急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年）
- 中南米の急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年）
- 中東・アフリカの急性骨髄性白血病（AML）バイオマーカー検査市場規模（2018年-2029年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
Abbott Laboratories、Novartis AG、Thermo Fisher Scientific、Cancer Genetics Inc.、Sysmex Corporation、Epigenomics AG、BioMerieux SA、Skyline DX B.V.

・アナリストの観点/結論

・調査手法と情報源

Highlights
The global Acute Myeloid Leukemia (AML) Biomarker Testing market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Acute Myeloid Leukemia (AML) Biomarker Testing is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Acute Myeloid Leukemia (AML) Biomarker Testing is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Acute Myeloid Leukemia (AML) Biomarker Testing in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Acute Myeloid Leukemia (AML) Biomarker Testing include Abbott Laboratories, Novartis AG, Thermo Fisher Scientific, Cancer Genetics Inc., Sysmex Corporation, Epigenomics AG, BioMerieux SA and Skyline DX B.V., etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Acute Myeloid Leukemia (AML) Biomarker Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Myeloid Leukemia (AML) Biomarker Testing.
The Acute Myeloid Leukemia (AML) Biomarker Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Acute Myeloid Leukemia (AML) Biomarker Testing market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Myeloid Leukemia (AML) Biomarker Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Abbott Laboratories
Novartis AG
Thermo Fisher Scientific
Cancer Genetics Inc.
Sysmex Corporation
Epigenomics AG
BioMerieux SA
Skyline DX B.V.
Segment by Type
Genetic Acute Myeloid Leukemia (AML) Biomarker
Epigenetic Acute Myeloid Leukemia (AML) Biomarker
Proteomic Acute Myeloid Leukemia (AML) Biomarker
Segment by Application
Hospitals
Cancer diagnostic Centers
Research Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Myeloid Leukemia (AML) Biomarker Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Genetic Acute Myeloid Leukemia (AML) Biomarker
1.2.3 Epigenetic Acute Myeloid Leukemia (AML) Biomarker
1.2.4 Proteomic Acute Myeloid Leukemia (AML) Biomarker
1.3 Market by Application
1.3.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Cancer diagnostic Centers
1.3.4 Research Institutes
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Perspective (2018-2029)
2.2 Acute Myeloid Leukemia (AML) Biomarker Testing Growth Trends by Region
2.2.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Acute Myeloid Leukemia (AML) Biomarker Testing Historic Market Size by Region (2018-2023)
2.2.3 Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Region (2024-2029)
2.3 Acute Myeloid Leukemia (AML) Biomarker Testing Market Dynamics
2.3.1 Acute Myeloid Leukemia (AML) Biomarker Testing Industry Trends
2.3.2 Acute Myeloid Leukemia (AML) Biomarker Testing Market Drivers
2.3.3 Acute Myeloid Leukemia (AML) Biomarker Testing Market Challenges
2.3.4 Acute Myeloid Leukemia (AML) Biomarker Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Players by Revenue
3.1.1 Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Players by Revenue (2018-2023)
3.1.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share by Players (2018-2023)
3.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Acute Myeloid Leukemia (AML) Biomarker Testing Revenue
3.4 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Concentration Ratio
3.4.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in 2022
3.5 Acute Myeloid Leukemia (AML) Biomarker Testing Key Players Head office and Area Served
3.6 Key Players Acute Myeloid Leukemia (AML) Biomarker Testing Product Solution and Service
3.7 Date of Enter into Acute Myeloid Leukemia (AML) Biomarker Testing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Acute Myeloid Leukemia (AML) Biomarker Testing Breakdown Data by Type
4.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Historic Market Size by Type (2018-2023)
4.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Type (2024-2029)
5 Acute Myeloid Leukemia (AML) Biomarker Testing Breakdown Data by Application
5.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Historic Market Size by Application (2018-2023)
5.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2018-2029)
6.2 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2018-2023)
6.4 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2018-2029)
7.2 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2018-2023)
7.4 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2018-2029)
8.2 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (2018-2023)
8.4 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2018-2029)
9.2 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2018-2023)
9.4 Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (2018-2029)
10.2 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2018-2023)
10.4 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.1.4 Abbott Laboratories Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
11.1.5 Abbott Laboratories Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Detail
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.2.4 Novartis AG Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
11.2.5 Novartis AG Recent Development
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Detail
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.3.4 Thermo Fisher Scientific Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
11.3.5 Thermo Fisher Scientific Recent Development
11.4 Cancer Genetics Inc.
11.4.1 Cancer Genetics Inc. Company Detail
11.4.2 Cancer Genetics Inc. Business Overview
11.4.3 Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.4.4 Cancer Genetics Inc. Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
11.4.5 Cancer Genetics Inc. Recent Development
11.5 Sysmex Corporation
11.5.1 Sysmex Corporation Company Detail
11.5.2 Sysmex Corporation Business Overview
11.5.3 Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.5.4 Sysmex Corporation Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
11.5.5 Sysmex Corporation Recent Development
11.6 Epigenomics AG
11.6.1 Epigenomics AG Company Detail
11.6.2 Epigenomics AG Business Overview
11.6.3 Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.6.4 Epigenomics AG Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
11.6.5 Epigenomics AG Recent Development
11.7 BioMerieux SA
11.7.1 BioMerieux SA Company Detail
11.7.2 BioMerieux SA Business Overview
11.7.3 BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.7.4 BioMerieux SA Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
11.7.5 BioMerieux SA Recent Development
11.8 Skyline DX B.V.
11.8.1 Skyline DX B.V. Company Detail
11.8.2 Skyline DX B.V. Business Overview
11.8.3 Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Introduction
11.8.4 Skyline DX B.V. Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
11.8.5 Skyline DX B.V. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Genetic Acute Myeloid Leukemia (AML) Biomarker
Table 3. Key Players of Epigenetic Acute Myeloid Leukemia (AML) Biomarker
Table 4. Key Players of Proteomic Acute Myeloid Leukemia (AML) Biomarker
Table 5. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Region (2018-2023)
Table 9. Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Region (2024-2029)
Table 11. Acute Myeloid Leukemia (AML) Biomarker Testing Market Trends
Table 12. Acute Myeloid Leukemia (AML) Biomarker Testing Market Drivers
Table 13. Acute Myeloid Leukemia (AML) Biomarker Testing Market Challenges
Table 14. Acute Myeloid Leukemia (AML) Biomarker Testing Market Restraints
Table 15. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Players (2018-2023)
Table 17. Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing as of 2022)
Table 18. Ranking of Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Acute Myeloid Leukemia (AML) Biomarker Testing Product Solution and Service
Table 22. Date of Enter into Acute Myeloid Leukemia (AML) Biomarker Testing Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share by Type (2018-2023)
Table 26. Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share by Type (2024-2029)
Table 28. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share by Application (2018-2023)
Table 30. Global Acute Myeloid Leukemia (AML) Biomarker Testing Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share by Application (2024-2029)
Table 32. North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 33. North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2024-2029) & (US$ Million)
Table 35. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2024-2029) & (US$ Million)
Table 38. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 39. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (2018-2023) & (US$ Million)
Table 40. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region (2024-2029) & (US$ Million)
Table 41. Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 42. Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2018-2023) & (US$ Million)
Table 43. Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2024-2029) & (US$ Million)
Table 44. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2018-2023) & (US$ Million)
Table 46. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country (2024-2029) & (US$ Million)
Table 47. Abbott Laboratories Company Detail
Table 48. Abbott Laboratories Business Overview
Table 49. Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Product
Table 50. Abbott Laboratories Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023) & (US$ Million)
Table 51. Abbott Laboratories Recent Development
Table 52. Novartis AG Company Detail
Table 53. Novartis AG Business Overview
Table 54. Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Product
Table 55. Novartis AG Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023) & (US$ Million)
Table 56. Novartis AG Recent Development
Table 57. Thermo Fisher Scientific Company Detail
Table 58. Thermo Fisher Scientific Business Overview
Table 59. Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Product
Table 60. Thermo Fisher Scientific Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023) & (US$ Million)
Table 61. Thermo Fisher Scientific Recent Development
Table 62. Cancer Genetics Inc. Company Detail
Table 63. Cancer Genetics Inc. Business Overview
Table 64. Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Product
Table 65. Cancer Genetics Inc. Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023) & (US$ Million)
Table 66. Cancer Genetics Inc. Recent Development
Table 67. Sysmex Corporation Company Detail
Table 68. Sysmex Corporation Business Overview
Table 69. Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Product
Table 70. Sysmex Corporation Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023) & (US$ Million)
Table 71. Sysmex Corporation Recent Development
Table 72. Epigenomics AG Company Detail
Table 73. Epigenomics AG Business Overview
Table 74. Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Product
Table 75. Epigenomics AG Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023) & (US$ Million)
Table 76. Epigenomics AG Recent Development
Table 77. BioMerieux SA Company Detail
Table 78. BioMerieux SA Business Overview
Table 79. BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Product
Table 80. BioMerieux SA Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023) & (US$ Million)
Table 81. BioMerieux SA Recent Development
Table 82. Skyline DX B.V. Company Detail
Table 83. Skyline DX B.V. Business Overview
Table 84. Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Product
Table 85. Skyline DX B.V. Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023) & (US$ Million)
Table 86. Skyline DX B.V. Recent Development
Table 87. Research Programs/Design for This Report
Table 88. Key Data Information from Secondary Sources
Table 89. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Type: 2022 VS 2029
Figure 3. Genetic Acute Myeloid Leukemia (AML) Biomarker Features
Figure 4. Epigenetic Acute Myeloid Leukemia (AML) Biomarker Features
Figure 5. Proteomic Acute Myeloid Leukemia (AML) Biomarker Features
Figure 6. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Application: 2022 VS 2029
Figure 8. Hospitals Case Studies
Figure 9. Cancer diagnostic Centers Case Studies
Figure 10. Research Institutes Case Studies
Figure 11. Others Case Studies
Figure 12. Acute Myeloid Leukemia (AML) Biomarker Testing Report Years Considered
Figure 13. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Region: 2022 VS 2029
Figure 16. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Players in 2022
Figure 17. Global Top Acute Myeloid Leukemia (AML) Biomarker Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Myeloid Leukemia (AML) Biomarker Testing as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in 2022
Figure 19. North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Country (2018-2029)
Figure 21. United States Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Canada Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Country (2018-2029)
Figure 25. Germany Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. France Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. U.K. Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Italy Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Russia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Nordic Countries Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Region (2018-2029)
Figure 33. China Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Japan Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. South Korea Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Southeast Asia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. India Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Australia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Country (2018-2029)
Figure 41. Mexico Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Brazil Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Country (2018-2029)
Figure 45. Turkey Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Saudi Arabia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Abbott Laboratories Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
Figure 48. Novartis AG Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
Figure 49. Thermo Fisher Scientific Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
Figure 50. Cancer Genetics Inc. Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
Figure 51. Sysmex Corporation Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
Figure 52. Epigenomics AG Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
Figure 53. BioMerieux SA Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
Figure 54. Skyline DX B.V. Revenue Growth Rate in Acute Myeloid Leukemia (AML) Biomarker Testing Business (2018-2023)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界の慢性骨髄性白血病治療市場2022年：市場規模予測（～2028年）
  • 急性リンパ芽球検査の世界市場2023年：Bリンパ球検査、Tリンパ球検査、その他
  • 腫瘍バイオマーカーの世界市場 2022年-2026年
  • 薬物乱用試験サービスの世界市場2023年：尿、唾液、毛髪、その他
  • ベアボードテストの世界市場2023年：ピン固定試験、フライングプローブ試験
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA7419 )"急性骨髄性白血病（AML）バイオマーカー検査の世界市場2023年：遺伝性急性骨髄性白血病（AML）バイオマーカー、エピジェネティック急性骨髄性白血病（AML）バイオマーカー、プロテオーム性急性骨髄性白血病（AML）バイオマーカー" (英文：Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。